Risk of hematologic toxicities in cancer patients treated with sunitinib: A systematic review and meta-analysis

Cancer Treatment Reviews

Volumn 39, Issue 7, 2013, Pages 818-830

  Funakoshi, Tomohiro ^a   Latif, Asma ^b   Galsky, Matthew D ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; Hematologic toxicities; Meta analysis; Neutropenia; Sunitinib; Thrombocytopenia

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; DOCETAXEL; INTERFERON; PACLITAXEL; PLACEBO; PREDNISONE; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANEMIA; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARCINOID; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; GASTROINTESTINAL STROMAL TUMOR; GERM CELL TUMOR; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INCIDENCE; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; META ANALYSIS; NASOPHARYNX CARCINOMA; NEUTROPENIA; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; STOMACH CANCER; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THYROID CANCER; TRANSITIONAL CELL CARCINOMA; UTERINE CERVIX CANCER; UTERUS SARCOMA; VON HIPPEL LINDAU DISEASE;

ANEMIA; HEMATOLOGIC TOXICITIES; META-ANALYSIS; NEUTROPENIA; SUNITINIB; THROMBOCYTOPENIA;

ANEMIA; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HEMATOLOGIC DISEASES; HUMANS; INCIDENCE; INDOLES; NEOPLASMS; NEUTROPENIA; PUBLICATION BIAS; PYRROLES; RISK; THROMBOCYTOPENIA;

EID: 84881544724     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.01.004     Document Type: Review

References (97)

1. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353(2):172-187.
2. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9(1):327-337.
3. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368(9544):1329-1338.
4. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27(22):3584-3590.
5. Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., Lombard-Bohas C., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(6):501-513.
6. Zhu X., Stergiopoulos K., Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009, 48(1):9-17.
7. Wu S., Chen J.J., Kudelka A., Lu J., Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008, 9(2):117-123.
8. Chu D., Lacouture M.E., Weiner E., Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 2009, 7(1):11-19.
9. Chu D., Lacouture M.E., Fillos T., Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008, 47(2):176-186.
10. Je Y., Schutz F.A., Choueiri T.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009, 10(10):967-974.
11. Choueiri T.K., Schutz F.A., Je Y., Rosenberg J.E., Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010, 28(13):2280-2285.
12. Schutz F.A., Je Y., Choueiri T.K. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. Crit Rev Oncol Hematol 2011, 80(2):291-300.
13. Gerber H.P., Malik A.K., Solar G.P., Sherman D., Liang X.H., Meng G., et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002, 417(6892):954-958.
14. Larrivee B., Lane D.R., Pollet I., Olive P.L., Humphries R.K., Karsan A. Vascular endothelial growth factor receptor-2 induces survival of hematopoietic progenitor cells. J Biol Chem 2003, 278(24):22006-22013.
15. Lyman S.D., Jacobsen S.E. C-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998, 91(4):1101-1134.
16. Nalluri SR, Su X, Shah R, et al. Risk of cytopenia with sunitinib in patients with renal cell cancer and non-RCC cancers: a meta-analysis. In Proceedings of the 2010 Genitourinary Cancers Symposium, ASCO, abstract 393.
17. Pfizer: Sutent prescribing information. http://www.pfizer.com/files/products/uspi_sutent.pdf.
18. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement. J Clin Epidemiol 2009, 62(10):1006-1012.
19. National Cancer Institute: Common Toxicity Criteria, version 3. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf.
20. Barrios C.H., Liu M.C., Lee S.C., Vanlemmens L., Ferrero J.M., Tabei T., et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010, 121(1):121-131.
21. Crown J., Dieras V., Staroslawska E., et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 2010, 28:18s. (suppl; abstr LBA1011).
22. Michaelson M.D., Oudard S., Ou Y., et al. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2011, 29. (suppl; abstr 4515).
23. Cheng A., Kang Y., Lin D., et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011, 29. (suppl; abstr 4000).
24. Bergh J., Bondarenko I.M., Lichinitser M.R., Liljegren A., Greil R., Voytko N.L., et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 2012, 30(9):921-929.
25. Socinski M.A., Scappaticci F.A., Samant M., Kolb M.M., Kozloff M.F. Safety and efficacy of combining sunitinib with bevacizumab+paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol 2010, 5(3):354-360.
26. Mayer E.L., Dhakil S., Patel T., Sundaram S., Fabian C., Kozloff M., et al. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 2010, 21(12):2370-2376.
27. Wildiers H., Fontaine C., Vuylsteke P., Martens M., Canon J.L., Wynendaele W., et al. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010, 123(2):463-469.
28. Negrier S., Gravis G., Perol D., Chevreau C., Delva R., Bay J.O., et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011, 12(7):673-680.
29. Yi J.H., Lee J., Park S.H., Park J.O., Yim D.S., Park Y.S., et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 2012, 106(9):1469-1474.
30. Motzer R.J., Hutson T.E., Olsen M.R., Hudes G.R., Burke J.M., Edenfield W.J., et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012, 30(12):1371-1377.
31. Grivas P., Nanus D.M., Stadler W.M., et al. Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC). J Clin Oncol 2012, 30. (suppl 5; abstr 265).
32. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24(1):16-24.
33. Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295(21):2516-2524.
34. Saltz L.B., Rosen L.S., Marshall J.L., Belt R.J., Hurwitz H.I., Eckhardt S.G., et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007, 25(30):4793-4799.
35. Socinski M.A., Novello S., Brahmer J.R., Rosell R., Sanchez J.M., Belani C.P., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008, 26(4):650-656.
36. Burstein H.J., Elias A.D., Rugo H.S., Cobleigh M.A., Wolff A.C., Eisenberg P.D., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26(11):1810-1816.
37. Kulke M.H., Lenz H.J., Meropol N.J., Posey J., Ryan D.P., Picus J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26(20):3403-3410.
38. Ravaud A., de la Fouchardière C., Courbon F., et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol 2008, 26. (May 20 suppl; abstr 6058).
39. George S., Blay J.Y., Casali P.G., Le Cesne A., Stephenson P., Deprimo S.E., et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009, 45(11):1959-1968.
40. Kontovinis L.F., Papazisis K.T., Touplikioti P., Andreadis C., Mouratidou D., Kortsaris A.H. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009, 9:82.
41. Dror Michaelson M., Regan M.M., Oh W.K., Kaufman D.S., Olivier K., Michaelson S.Z., et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009, 20(5):913-920.
42. George S., Merriam P., Maki R.G., Van den Abbeele A.D., Yap J.T., Akhurst T., et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009, 27(19):3154-3160.
43. Zhu A.X., Sahani D.V., Duda D.G., di Tomaso E., Ancukiewicz M., Catalano O.A., et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009, 27(18):3027-3035.
44. Feldman D.R., Turkula S., Ginsberg M.S., Ishill N., Patil S., Carousso M., et al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs 2010, 28(4):523-528.
45. Faivre S., Raymond E., Boucher E., Douillard J., Lim H.Y., Kim J.S., et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009, 10(8):794-800.
46. Gore M.E., Szczylik C., Porta C., Bracarda S., Bjarnason G.A., Oudard S., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009, 10(8):757-763.
47. Sonpavde G., Periman P.O., Bernold D., Weckstein D., Fleming M.T., Galsky M.D., et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010, 21(2):319-324.
48. Choong N.W., Kozloff M., Taber D., Hu H.S., Wade J., Ivy P., et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs 2010, 28(5):677-683.
49. Escudier B., Roigas J., Gillessen S., Harmenberg U., Srinivas S., Mulder S.F., et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27(25):4068-4075.
50. Fountzilas G., Fragkoulidi A., Kalogera-Fountzila A., Nikolaidou M., Bobos M., Calderaro J., et al. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol 2010, 65(4):649-660.
51. Mackay H.J., Tinker A., Winquist E., Thomas G., Swenerton K., Oza A., et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 2010, 116(2):163-167.
52. Hensley M.L., Sill M.W., Scribner D.R., Brown J., Debernardo R.L., Hartenbach E.M., et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a gynecologic oncology group phase II study. Gynecol Oncol 2009, 115(3):460-465.
53. Novello S., Scagliotti G.V., Rosell R., Socinski M.A., Brahmer J., Atkins J., et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009, 101(9):1543-1548.
54. Machiels J.P., Henry S., Zanetta S., Kaminsky M.C., Michoux N., Rommel D., et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010, 28(1):21-28.
55. Gallagher D.J., Milowsky M.I., Gerst S.R., Ishill N., Riches J., Regazzi A., et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010, 28(8):1373-1379.
56. Koeberle D., Montemurro M., Samaras P., Majno P., Simcock M., Limacher A., et al. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 2010, 15(3):285-292.
57. Ping G., Hui-Min W., Wei-Min W., Bao-Hui H. Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population. Med Oncol 2011, 28(2):578-583.
58. Bang Y.J., Kang Y.K., Kang W.K., Boku N., Chung H.C., Chen J.S., et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2011, 29(6):1449-1458.
59. Hellenthal N.J., Underwood W., Penetrante R., Litwin A., Zhang S., Wilding G.E., et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010, 184(3):859-864.
60. Biagi J.J., Oza A.M., Chalchal H.I., Grimshaw R., Ellard S.L., Lee U., et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 2011, 22(2):335-340.
61. Molina A.M., Feldman D.R., Ginsberg M.S., Kroog G., Tickoo S.K., Jia X., et al. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs 2012, 30(1):335-340.
62. Tomita Y., Shinohara N., Yuasa T., Fujimoto H., Niwakawa M., Mugiya S., et al. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2010, 40(12):1166-1172.
63. Carr L.L., Mankoff D.A., Goulart B.H., Eaton K.D., Capell P.T., Kell E.M., et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010, 16(21):5260-5268.
64. Neyns B., Sadones J., Chaskis C., Dujardin M., Everaert H., Lv S., et al. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol 2011, 103(3):491-501.
65. Shanafelt T., Zent C., Byrd J., Erlichman C., Laplant B., Ghosh A., et al. Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leukemia Lymphoma 2010, 51(12):2222-2229.
66. O'Reilly E.M., Niedzwiecki D., Hall M., Hollis D., Bekaii-Saab T., Pluard T., et al. A cancer and leukemia group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist 2010, 15(12):1310-1319.
67. Correa R., Mackay H., Hirte H.W., et al. A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: a trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia. J Clin Oncol 2010, 28:15s. (suppl; abstr 5038).
68. De Souza J.A., Busaidy N., Zimrin A., et al. Phase II trial of sunitinib in medullary thyroid cancer (MTC). J Clin Oncol 2010, 28:15s. (suppl; abstr 5504).
69. Decoster L., Neyns B. Vande Broek I et al. Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers. J Clin Oncol 2010, 28:15s.
70. Nowak A.K., Millward M., Francis R.J., et al. Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). J Clin Oncol 2010, 28:15s.
71. Hui E.P., Ma B.B., King A.D., Mo F., Chan S.L., Kam M.K., et al. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol 2011, 22(6):1280-1287.
72. Bellmunt J., Gonzalez-Larriba J.L., Prior C., Maroto P., Carles J., Castellano D., et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011, 22(12):2646-2653.
73. Buckstein R., Kuruvilla J., Chua N., Lee C., Macdonald D.A., Al-Tourah A.J., et al. Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group. Leukemia Lymphoma 2011, 52(5):833-841.
74. Schneider B.J., Gadgeel S.M., Ramnath N., Wozniak A.J., Dy G.K., Daignault S., et al. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer. J Thorac Oncol 2011, 6(6):1117-1120.
75. Moehler M., Mueller A., Hartmann J.T., Ebert M.P., Al-Batran S.E., Reimer P., et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer 2011, 47(10):1511-1520.
76. Novello S., Camps C., Grossi F., Mazieres J., Abrey L., Vernejoux J.M., et al. Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases. J Thorac Oncol 2011, 6(7):1260-1266.
77. Gervais R., Hainsworth J.D., Blais N., Besse B., Laskin J., Hamm J.T., et al. Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer 2011, 74(3):474-480.
78. Bex A., Blank C., Meinhardt W., van Tinteren H., Horenblas S., Haanen J. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. Urology 2011, 78(4):832-837.
79. Barrios C.H., Hernandez-Barajas D., Brown M.P., Lee S.H., Fein L., Liu J.H., et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 2012, 118(5):1252-1259.
80. Laurie S.A., Gupta A., Chu Q., Lee C.W., Morzycki W., Feld R., et al. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC clinical trials group. J Thorac Oncol 2011, 6(11):1950-1954.
81. Jonasch E., McCutcheon I.E., Waguespack S.G., Wen S., Davis D.W., Smith L.A., et al. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol 2011, 22(12):2661-2666.
82. Yi J.H., Thongprasert S., Lee J., Doval D.C., Park S.H., Park J.O., et al. A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer 2012, 48(2):196-201.
83. Chevreau C., Ravaud A., Escudier B., et al. Phase II trial of sunitinib in renal cell cancer with untreated brain metastases. J Clin Oncol 2011, 29. (suppl; abstr 4625).
84. Reynolds C., Spira A.I., Gluck W.L., et al. Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients. J Clin Oncol 2011, 29. (suppl; abstr 7549).
85. Lee J.L., Ahn J.H., Lim H.Y., Park S.H., Lee S.H., Kim T.M., et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol 2012, 23(8):2108-2114.
86. Sterne J.A., Gavaghan D., Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000, 53(11):1119-1129.
87. Schutz F.A., Jardim D.L., Je Y., Choueiri T.K. Haematologic toxicities associated with the addition of bevacizumab in cancer patients. Eur J Cancer 2011, 47(8):1161-1174.
88. Barni S., Cabiddu M., Guarneri P., Lonati V., Petrelli F. The risk for anemia with targeted therapies for solid tumors. Oncologist 2012, 17(5):715-724.
89. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26(1):127-132.
90. Kimura Y., Ding B., Imai N., Nolan D.J., Butler J.M., Rafii S. C-Kit-mediated functional positioning of stem cells to their niches is essential for maintenance and regeneration of adult hematopoiesis. PloS One 2011, 6(10):e26918.
91. Weisel K.C., Yildirim S., Schweikle E., Kanz L., Mohle R. Effect of FLT3 inhibition on normal hematopoietic progenitor cells. Ann N Y Acad Sci 2007, 1106:190-196.
92. Mackarehtschian K., Hardin J.D., Moore K.A., Boast S., Goff S.P., Lemischka I.R. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995, 3(1):147-161.
93. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28(6):1061-1068.
94. Kumar R., Crouthamel M.C., Rominger D.H., Gontarek R.R., Tummino P.J., Levin R.A., et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009, 101(10):1717-1723.
95. Crawford J., Dale D.C., Lyman G.H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004, 100(2):228-237.
96. Galsky M.D., Hellerstedt B.A., O'Rourke M.A., et al. Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma. J Clin Oncol 2012, 30. (suppl 5; abstr 282).
97. Bhojani N., Jeldres C., Patard J.J., Perrotte P., Suardi N., Hutterer G., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008, 53(5):917-930.